Search

Your search keyword '"Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425)"' showing total 54 results

Search Constraints

Start Over You searched for: Author "Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425)" Remove constraint Author: "Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425)"
54 results on '"Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425)"'

Search Results

1. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort

2. Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation

3. Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study

4. Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial

5. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial

6. Impact of corticosteroids use on midterm sequelae in survivors of COVID-19 admitted to hospital: A prospective cohort study

7. Empirical Treatment in Acute Bacterial Meningitis: a Plea for High Doses of Cefotaxime or Ceftriaxone

8. Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort

9. Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial

10. Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children

11. Prediction models of methicillin sensitive Staphylococcus aureus ventilator associated pneumonia relapse in trauma and brain injury patients: A retrospective analysis

12. Staphylococcus aureus endocarditis: Identifying prognostic factors using a method derived from morbidity and mortality conferences

13. Relationship between serotypes, disease characteristics and 30-day mortality in adults with invasive pneumococcal disease

14. A Clinical Study Provides the First Direct Evidence That Interindividual Variations in Fecal β-Lactamase Activity Affect the Gut Mycobiota Dynamics in Response to β-Lactam Antibiotics

15. Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study)

16. Risk factors for therapeutic failure in the management of post-operative peritonitis: a post hoc analysis of the DURAPOP trial

17. Combined Bacterial Meningitis and Infective Endocarditis: When Should We Search for the Other When Either One is Diagnosed?

18. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

19. Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

20. One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study

21. The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas

22. Guidelines on enhanced recovery after cardiac surgery under cardiopulmonary bypass or off-pump

23. Extracorporeal Membrane Oxygenation for Respiratory Failure Related to COVID-19: A Nationwide Cohort Study

24. A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT ‐0701 MAPS phase 3 trial

25. In-hospital and midterm out-hospital complications of adults hospitalised with respiratory syncytial virus infection in France, 2017-2019: an observational study

26. Poor oral health and hygiene habits in patients with infective endocarditis and previously identified predisposing cardiac condition: A prospective cohort study

27. Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav

28. Hypermetabolism of the spleen or bone marrow is an additional albeit indirect sign of infective endocarditis at FDG-PET

29. Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study

30. High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea

31. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

32. Caffeine intake exerts dual genome-wide effects on hippocampal metabolism and learning-dependent transcription

33. Accuracy of citrulline, I-FABP and d-lactate in the diagnosis of acute mesenteric ischemia

34. Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19: a prospective cohort study

35. Effectiveness of a Multifaceted Informational-Based and Text Message Reminders on Pneumococcal and Influenza Vaccinations in Hospital Emergency Departments: A Cluster-Randomized Controlled Trial

36. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

37. Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes

38. CSF concentration of cefotaxime in adult patients with pneumococcal meningitis: a multicentre retrospective study

39. Hepcidin and Iron Deficiency in Women One Year after Sleeve Gastrectomy: A Prospective Cohort Study

40. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

41. Contribution of vaginal culture to predict early onset neonatal infection in preterm prelabor rupture of membranes

42. Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak

43. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

44. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort

45. Chronic use of Renin‐Angiotensin‐Aldosterone‐System blockers and mortality in COVID‐19: a multicenter prospective cohort and literature review

46. Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial

47. Is the Alpha Variant of SARS-CoV-2 Associated with a Higher Viral Load Than the Historical Strain in Saliva Samples in Patients with Mild to Moderate Symptoms?

48. Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19

49. Response to Letter to the Editor from Woolcott and Castilla-Bancayán: 'Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults'

50. Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV

Catalog

Books, media, physical & digital resources